Kuhnen C, Lehnhardt M, Tolnay E, Muehlberger T, Vogt P M, Müller K M
Institute of Pathology, University Hospital Bergmannsheil, Bochum, Germany.
J Cancer Res Clin Oncol. 2000 Apr;126(4):219-25. doi: 10.1007/s004320050036.
Vascular endothelial growth factor (VEGF) is an important cytokine especially in the process of tumour angiogenesis. A total of 46 soft-tissue sarcomas were analysed for the expression and possible secretion of VEGF by immunohistochemistry, in-situ hybridisation, and enzyme-linked immunosorbent assays (ELISA). VEGF was demonstrated immunohistochemically in tumour tissue in 45 of 46 cases. The detection of mRNA transcripts yielded evidence of synthesis of VEGF in these sarcomas. ELISA could be performed in 21 cases. Higher concentrations of VEGF were found in tumour-related intraoperatively sampled venous blood in 16 out of 21 patients (76%) than in systemic concentrations taken preoperatively. The results indicated the secretion of VEGF by tumour cells although these raised concentrations were not statistically significant. In 12 out of these 16 patients (75%) a concurrent moderate to strong immunoexpression of VEGF was detected. The relevance of VEGF blood concentrations as a potential "progress parameter" for the course of disease remains questionable. This is mainly due to the lack of statistical significance in the difference between systemic VEGF concentrations in patients and those of a control group. Further long-term follow-up studies are needed, which should include patients with tumour recurrences.
血管内皮生长因子(VEGF)是一种重要的细胞因子,尤其在肿瘤血管生成过程中。通过免疫组织化学、原位杂交和酶联免疫吸附测定(ELISA)对46例软组织肉瘤进行了VEGF表达及可能的分泌情况分析。46例病例中有45例在肿瘤组织中通过免疫组织化学检测到VEGF。mRNA转录本的检测证实了这些肉瘤中VEGF的合成。21例病例可进行ELISA检测。21例患者中有16例(76%)术中采集的肿瘤相关静脉血中VEGF浓度高于术前采集的全身浓度。结果表明肿瘤细胞分泌VEGF,尽管这些升高的浓度无统计学意义。在这16例患者中有12例(75%)同时检测到VEGF中度至强免疫表达。VEGF血浓度作为疾病进程潜在“进展参数”的相关性仍存在疑问。这主要是由于患者全身VEGF浓度与对照组之间差异缺乏统计学意义。需要进一步进行长期随访研究,其中应包括肿瘤复发患者。